Overall Detection Rate in Patients with PSA Values ≤ 0.2 ng/mL (Patients 1–26)
| Patient no. | PSA (ng/mL) | ADT | RT | LR | SUVmax | LN met. | SUVmax | LN size (mm) | LN location* | BM | SUVmax | Dose (MBq) |
| 1 | 0.03 | Previous | − | + | 6.1 | 3 | 1 | − | 138 | |||
| 2 | 0.05 | − | + | 3.9 | 4 | 1 | − | 107 | ||||
| 3 | 0.05 | − | − | − | 120 | |||||||
| 4 | 0.06 | − | − | − | 115 | |||||||
| 5 | 0.07 | − | − | − | 153 | |||||||
| 6 | 0.08 | Ongoing | − | + | 17.1 | 4 | 2 | − | 90 | |||
| 7 | 0.08 | − | − | − | 114 | |||||||
| 8 | 0.08 | − | − | − | 115 | |||||||
| 9 | 0.09 | − | − | − | 146 | |||||||
| 10 | 0.1 | aRT | − | − | − | 154 | ||||||
| 11 | 0.11 | − | − | − | 143 | |||||||
| 12 | 0.12 | − | − | − | 120 | |||||||
| 13 | 0.13 | − | − | − | 150 | |||||||
| 14 | 0.13 | − | − | − | 110 | |||||||
| 15 | 0.14 | sRT | − | − | + | 4.1 | 113 | |||||
| 16 | 0.14 | + | 4 | − | − | 120 | ||||||
| 17 | 0.15 | sRT | − | + | 15 | 8 | 1 | − | 126 | |||
| 18 | 0.15 | + | 4.5 | − | − | 140 | ||||||
| 19 | 0.16 | + | 5.3 | − | + | 4.65 | 126 | |||||
| 20 | 0.16 | + | 10.8 | − | − | 128 | ||||||
| 21 | 0.16 | − | − | − | 107 | |||||||
| 22 | 0.17 | − | − | − | 102 | |||||||
| 23 | 0.17 | − | − | − | 152 | |||||||
| 24 | 0.17 | − | − | − | 113 | |||||||
| 25 | 0.18 | sRT | − | + | 12.4 | 8 | 1 | − | 104 | |||
| 26 | 0.19 | − | − | − | 134 |
↵* 1 = pelvic; 2 = paraaortal; 3 = mediastinal/supraclavicular; 4 = axillary.
LR = local recurrence; LN met. = lymph node metastasis; LN = lymph node; BM = bone metastasis; aRT = adjuvant radiotherapy.